G protein-coupled receptor systems and their lipid environment in health disorders during aging

Biochimica et Biophysica Acta - Biomembranes

Volumn 1768, Issue 4, 2007, Pages 964-975

  Alemany, Regina ^a   Perona, Javier S ^a   Sánchez Dominguez, José M ^a   Montero, Emilio ^b   Cañizares, Julio ^c   Bressani, Ricardo ^d   Escribá, Pablo V ^a   Ruiz Gutierrez, Valentina ^a  

^a INSTITUTO DE LA GRASA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^c Virgen del Rocío Hospital ^*  (Spain)

^d University of Guatemala   (Guatemala)

Author keywords

Aging; Fatty acid; G protein coupled receptor; Human pathology; Lipid membrane composition; Signaling protein

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; MEMBRANE LIPID; PROTEIN TYROSINE KINASE;

AGED; AGING; CANCER; CARDIOVASCULAR DISEASE; CELL CYCLE ARREST; CELL MEMBRANE; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LIPID COMPOSITION; LIPID MEMBRANE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; REGULATORY MECHANISM; REVIEW; SENESCENCE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

AGING; DISEASE; HUMANS; MEMBRANE LIPIDS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 33947424778     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2006.09.024     Document Type: Review

References (187)

1. Harman D. Aging: overview. Ann. N. Y. Acad. Sci. 928 (2001) 1-21
2. Smith J.R., and Pereira-Smith O.M. Replicative senescence: implications for in vivo aging and tumor suppression. Science 273 (1996) 63-67
3. Yeo E.J., Jang I.S., Lim H.K., Ha K.S., and Park S.C. Agonist-specific differential changes of cellular signal transduction pathways in senescent human diploid fibroblasts. Exp. Gerontol. 37 (2002) 871-883
4. Yeo E.J., and Park S.C. Age-dependent agonist-specific dysregulation of membrane-mediated signal transduction: emergence of the gate theory of aging. Mech. Ageing Dev. 123 (2002) 1563-1578
5. Bargmann C.I. Neurobiology of the Caenorhabditis elegans genome. Science 282 (1998) 2028-2033
6. Marchese A., George S.R., Kolakowski Jr. L.F., Lynch K.R., and O'Dowd B.F. Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology. Trends Pharmacol. Sci. 20 (1999) 370-375
7. Hausdorff W.P., Caron M.G., and Lefkowitz R.J. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J. 4 (1990) 2881-2889
8. Krupnick J.G., and Benovic J.L. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 289-319
9. Funari S.S., Barcelo F., and Escriba P.V. Effects of oleic acid and its congeners, elaidic and stearic acids, on the structural properties of phosphatidylethanolamine membranes. J. Lipid Res. 44 (2003) 567-575
10. Vogler O., Casas J., Capo D., Nagy T., Borchert G., Martorell G., and Escriba P.V. The Gbetagamma dimer drives the interaction of heterotrimeric Gi proteins with nonlamellar membrane structures. J. Biol. Chem. 279 (2004) 36540-36545
11. Choe M., Jackson C., and Yu B.P. Lipid peroxidation contributes to age-related membrane rigidity. Free Radic. Biol. Med. 18 (1995) 977-984
12. Hulbert A.J. On the importance of fatty acid composition of membranes for aging. J. Theor. Biol. 234 (2005) 277-288
13. Escriba P.V., Ferrer-Montiel A.V., Ferragut J.A., and Gonzalez-Ros J.M. Role of membrane lipids in the interaction of daunomycin with plasma membranes from tumor cells: implications in drug-resistance phenomena. Biochemistry 29 (1990) 7275-7282
14. Escriba P.V., Sastre M., and Garcia-Sevilla J.A. Disruption of cellular signaling pathways by daunomycin through destabilization of nonlamellar membrane structures. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7595-7599
15. Giorgione J., Epand R., Buda C., and Farkas T. Role of phospholipids containing docosahexaenoyl chains in modulating the activity of protein kinase C. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9767-9770
16. Basanez G., Nieva J.L., Goni F.M., and Alonso A. Origin of the lag period in the phospholipase C cleavage of phospholipids in membranes. Concomitant vesicle aggregation and enzyme activation. Biochemistry 35 (1996) 15183-15187
17. Ahyayauch H., Villar A.V., Alonso A., and Goni F.M. Modulation of PI-specific phospholipase C by membrane curvature and molecular order. Biochemistry 44 (2005) 11592-11600
18. Zicha J., Kunes J., and Devycnk M.A. Abnormalities of membrane function and lipid metabolism in hypertension. Am. J. Hypertens. 12 (1999) 315-331
19. Buchet R., and Pikula S. Alzheimer's disease: its origin at the membrane, evidence and questions. Acta Biochim. Pol. 47 (2000) 725-733
20. Wells K., Farooqui A.A., Liss L., and Horrocks L.A. Neural membrane phospholipids in Alzheimer disease. Neurochem. Res. 20 (1995) 1329-1333
21. Caprari P., Scuteri A., Salvati A.M., Bauco C., Cantafora A., Masella R., Modesti D., Tarzia A., and Marigliano V. Aging and red blood cell membrane: a study of centenarians. Exp. Gerontol. 34 (1999) 47-57
22. Noble J.M., Thomas T.H., and Ford G.A. Effect of age on plasma membrane asymmetry and membrane fluidity in human leukocytes and platelets. J. Gerontol., A, Biol. Sci. Med. Sci. 54 (1999) M601-M606
23. Escriba P.V., Sanchez-Dominguez J.M., Alemany R., Perona J.S., and Ruiz-Gutierrez V. Alteration of lipids, G proteins, and PKC in cell membranes of elderly hypertensives. Hypertension 41 (2003) 176-182
24. Martin-Moreno J.M., Willett W.C., Gorgojo L., Banegas J.R., Rodriguez-Artalejo F., Fernandez-Rodriguez J.C., Maisonneuve P., and Boyle P. Dietary fat, olive oil intake and breast cancer risk. Int. J. Cancer 58 (1994) 774-780
25. De la Puerta R., Martinez-Dominguez E., and Ruiz-Gutierrez V. Effect of minor components of virgin olive oil on topical antiinflammatory assays. Z. Naturforsch., C 55 (2000) 814-819
26. Ferrara L.A., Raimondi A.S., d'Episcopo L., Guida L., Dello Russo A., and Marotta T. Olive oil and reduced need for antihypertensive medications. Arch. Intern. Med. 160 (2000) 837-842
27. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., and Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21 (2001) 8370-8377
28. Barcelo-Coblijn G., Hogyes E., Kitajka K., Puskas L.G., Zvara A., Hackler Jr. L., Nyakas C., Penke Z., and Farkas T. Modification by docosahexaenoic acid of age-induced alterations in gene expression and molecular composition of rat brain phospholipids. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11321-11326
29. Barcelo-Coblijn G., Kitajka K., Puskas L.G., Hogyes E., Zvara A., Hackler Jr. L., and Farkas T. Gene expression and molecular composition of phospholipids in rat brain in relation to dietary n-6 to n-3 fatty acid ratio. Biochim. Biophys. Acta 1632 (2003) 72-79
30. Perona J.S., Canizares J., Montero E., Sanchez-Dominguez J.M., Catala A., and Ruiz-Gutierrez V. Virgin olive oil reduces blood pressure in hypertensive elderly subjects. Clin. Nutr. 23 (2004) 1113-1121
31. Lane R.M., and Farlow M.R. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J. Lipid Res. 46 (2005) 949-968
32. Estruch R., Martinez-González M.A., Corella D., Salas-Salvadó J., Ruiz-Gutierrez V., Covas M.I., Fiol M., Gómez-Gracia E., López-Sabater M.C., Vinyoles E., Arós F., Conde M., Lahoz C., Lapetra J., Sáez G., and Ros E. Effects of a Mediterranean-style diet on cardiovascular risk factors. Ann. Int. Med. 145 (2006) 1-11
33. Carreca I., Balducci L., and Extermann M. Cancer in the older person. Cancer Treat. Rev. 31 (2005) 380-402
34. Walter L.C., Lewis C.L., and Barton M.B. Screening for colorectal, breast, and cervical cancer in the elderly: a review of the evidence. Am. J. Med. 118 (2005) 1078-1086
35. Wrensch M., Minn Y., Chew T., Bondy M., and Berger M.S. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro-oncol. 4 (2002) 278-299
36. van Biesen T., Luttrell L.M., Hawes B.E., and Lefkowitz R.J. Mitogenic signaling via G protein-coupled receptors. Endocr. Rev. 17 (1996) 698-714
37. Dhanasekaran N., and Prasad M.V. G protein subunits and cell proliferation. Biol. Signals Recept. 7 (1998) 109-117
38. Dhanasekaran N., Tsim S.T., Dermott J.M., and Onesime D. Regulation of cell proliferation by G proteins. Oncogene 17 (1998) 1383-1394
39. Gutkind J.S. Cell growth control by G protein-coupled receptors: from signal transduction to signal integration. Oncogene 17 (1998) 1331-1342
40. Li S., Huang S., and Peng S.B. Overexpression of G protein-coupled receptors in cancer cells: involvement in tumor progression. Int. J. Oncol. 27 (2005) 1329-1339
41. Dhanasekaran N., Heasley L.E., and Johnson G.L. G protein-coupled receptor systems involved in cell growth and oncogenesis. Endocr. Rev. 16 (1995) 259-270
42. Gudermann T., Grosse R., and Schultz G. Contribution of receptor/G protein signaling to cell growth and transformation. Naunyn-Schmiedeberg's Arch. Pharmacol. 361 (2000) 345-362
43. Sethi T., Langdon S., Smyth J., and Rozengurt E. Growth of small cell lung cancer cells: stimulation by multiple neuropeptides and inhibition by broad spectrum antagonists in vitro and in vivo. Cancer Res. 52 (1992) 2737s-2742s
44. Rozengurt E. Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. Curr. Opin. Oncol. 11 (1999) 116-122
45. Reubi J.C. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24 (2003) 389-427
46. Beekman A., Helfrich B., Bunn Jr. P.A., and Heasley L.E. Expression of catalytically inactive phospholipase Cbeta disrupts phospholipase Cbeta and mitogen-activated protein kinase signaling and inhibits small cell lung cancer growth. Cancer Res. 58 (1998) 910-913
47. Seufferlein T., and Rozengurt E. Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res. 56 (1996) 5758-5764
48. Jones D.A., Cummings J., Langdon S.P., and Smyth J.F. Preclinical studies on the broad-spectrum neuropeptide growth factor antagonist G. Gen. Pharmacol. 28 (1997) 183-189
49. Paschke R., and Ludgate M. The thyrotropin receptor in thyroid diseases. N. Engl. J. Med. 337 (1997) 1675-1681
50. Gudermann T., Kalkbrenner F., and Schultz G. Diversity and selectivity of receptor-G protein interaction. Annu. Rev. Pharmacol. Toxicol. 36 (1996) 429-459
51. Laugwitz K.L., Allgeier A., Offermanns S., Spicher K., Van Sande J., Dumont J.E., and Schultz G. The human thyrotropin receptor: a heptahelical receptor capable of stimulating members of all four G protein families. Proc. Natl. Acad. Sci. U. S. A. 93 (1996) 116-120
52. Vassart G., and Dumont J.E. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr. Rev. 13 (1992) 596-611
53. O'Sullivan C., Barton C.M., Staddon S.L., Brown C.L., and Lemoine N.R. Activating point mutations of the gsp oncogene in human thyroid adenomas. Mol. Carcinog. 4 (1991) 345-349
54. Suarez H.G., du Villard J.A., Caillou B., Schlumberger M., Parmentier C., and Monier R. gsp mutations in human thyroid tumours. Oncogene 6 (1991) 677-679
55. Shenker A., Laue L., Kosugi S., Merendino Jr. J.J., Minegishi T., and Cutler Jr. G.B. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty. Nature 365 (1993) 652-654
56. Voigt C., Holzapfel H.P., Meyer S., and Paschke R. Increased expression of G-protein-coupled receptor kinases 3 and 4 in hyperfunctioning thyroid nodules. J. Endocrinol. 182 (2004) 173-182
57. Pujol P., Daures J.P., Nsakala N., Baldet L., Bringer J., and Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J. Clin. Endocrinol. Metab. 81 (1996) 4318-4323
58. Carmeci C., Thompson D.A., Ring H.Z., Francke U., and Weigel R.J. Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45 (1997) 607-617
59. Filardo E.J., Quinn J.A., Bland K.I., and Frackelton Jr. A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 14 (2000) 1649-1660
60. Maggiolini M., Vivacqua A., Fasanella G., Recchia A.G., Sisci D., Pezzi V., Montanaro D., Musti A.M., Picard D., and Ando S. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J. Biol. Chem. 279 (2004) 27008-27016
61. Thomas P., Pang Y., Filardo E.J., and Dong J. Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146 (2005) 624-632
62. Porter A.T., F. A.C.R.O., and Ben-Josef E. Humoral mechanisms in prostate cancer: A role for FSH. Urol. Oncol. 6 (2001) 131-138
63. Daaka Y. Mitogenic action of LPA in prostate. Biochim. Biophys. Acta 1582 (2002) 265-269
64. Nelson J., Bagnato A., Battistini B., and Nisen P. The endothelin axis: emerging role in cancer. Nat. Rev., Cancer 3 (2003) 110-116
65. Bookout A.L., Finney A.E., Guo R., Peppel K., Koch W.J., and Daaka Y. Targeting Gbetagamma signaling to inhibit prostate tumor formation and growth. J. Biol. Chem. 278 (2003) 37569-37573
66. Itoh Y., Joh T., Tanida S., Sasaki M., Kataoka H., Itoh K., Oshima T., Ogasawara N., Togawa S., Wada T., Kubota H., Mori Y., Ohara H., Nomura T., Higashiyama S., and Itoh M. IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. Cytokine 29 (2005) 275-282
67. Hendrich A.B., and Michalak K. Lipids as a target for drugs modulating multidrug resistance of cancer cells. Curr. Drug Targets 4 (2003) 23-30
68. Mikirova N., Riordan H.D., Jackson J.A., Wong K., Miranda-Massari J.R., and Gonzalez M.J. Erythrocyte membrane fatty acid composition in cancer patients. P. R. Health Sci. J. 23 (2004) 107-113
69. Escriba P.V., Ozaita A., Ribas C., Miralles A., Fodor E., Farkas T., and Garcia-Sevilla J.A. Role of lipid polymorphism in G protein-membrane interactions: nonlamellar-prone phospholipids and peripheral protein binding to membranes. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 11375-11380
70. Martinez J., Vogler O., Casas J., Barcelo F., Alemany R., Prades J., Nagy T., Baamonde C., Kasprzyk P.G., Teres S., Saus C., and Escriba P.V. Membrane structure modulation, protein kinase C alpha activation, and anticancer activity of minerval. Mol. Pharmacol. 67 (2005) 531-540
71. Yang Q., Alemany R., Casas J., Kitajka K., Lanier S.M., and Escriba P.V. Influence of the membrane lipid structure on signal processing via G protein-coupled receptors. Mol. Pharmacol. 68 (2005) 210-217
72. Escriba P.V. Membrane-lipid therapy: a new approach in molecular medicine. Trends Mol. Med. 12 (2006) 34-43
73. Joseph J.A., Cutler R., and Roth G.S. Changes in G protein-mediated signal transduction in aging and Alzheimer's disease. Ann. N. Y. Acad. Sci. 695 (1993) 42-45
74. Pascual J., del Arco C., Gonzalez A.M., Diaz A., del Olmo E., and Pazos A. Regionally specific age-dependent decline in alpha 2-adrenoceptors: an autoradiographic study in human brain. Neurosci. Lett. 133 (1991) 279-283
75. Sastre M., and Garcia-Sevilla J.A. Density of alpha-2A adrenoceptors and Gi proteins in the human brain: ratio of high-affinity agonist sites to antagonist sites and effect of age. J. Pharmacol. Exp. Ther. 269 (1994) 1062-1072
76. Sastre M., Guimon J., and Garcia-Sevilla J.A. Relationships between beta- and alpha2-adrenoceptors and G coupling proteins in the human brain: effects of age and suicide. Brain Res. 898 (2001) 242-255
77. Mato S., and Pazos A. Influence of age, postmortem delay and freezing storage period on cannabinoid receptor density and functionality in human brain. Neuropharmacology 46 (2004) 716-726
78. 3H]CGP 12177. Eur. J. Pharmacol. 167 (1989) 397-405
79. Vijayashankar N., and Brody H. A quantitative study of the pigmented neurons in the nuclei locus coeruleus and subcoeruleus in man as related to aging. J. Neuropathol. Exp. Neurol. 38 (1979) 490-497
80. 2 with monoamine oxidase-B sites. J. Neurochem. 61 (1993) 881-889
81. Jones D.T., and Reed R.R. Molecular cloning of five GTP-binding protein cDNA species from rat olfactory neuroepithelium. J. Biol. Chem. 262 (1987) 14241-14249
82. Simonds W.F., Goldsmith P.K., Codina J., Unson C.G., and Spiegel A.M. Gi2 mediates alpha 2-adrenergic inhibition of adenylyl cyclase in platelet membranes: in situ identification with G alpha C-terminal antibodies. Proc. Natl. Acad. Sci. U. S. A. 86 (1989) 7809-7813
83. Marullo S., Emorine L.J., Strosberg A.D., and Delavier-Klutchko C. Selective binding of ligands to beta 1, beta 2 or chimeric beta 1/beta 2-adrenergic receptors involves multiple subsites. EMBO J. 9 (1990) 1471-1476
84. Young L.T., Warsh J.J., Li P.P., Siu K.P., Becker L., Gilbert J., Hornykiewicz O., and Kish S.J. Maturational and aging effects on guanine nucleotide binding protein immunoreactivity in human brain. Brain Res. Dev. Brain Res. 61 (1991) 243-248
85. Cowburn R.F., Marcusson J.O., Eriksson A., Wiehager B., and O'Neill C. Adenylyl cyclase activity and G-protein subunit levels in postmortem frontal cortex of suicide victims. Brain Res. 633 (1994) 297-304
86. Shimohama S., Ninomiya H., Saitoh T., Terry R.D., Fukunaga R., Taniguchi T., Fujiwara M., Kimura J., and Kameyama M. Changes in signal transduction in Alzheimer's disease. J. Neural Transm. Suppl. 30 (1990) 69-78
87. Jope R.S., Song L., Li X., and Powers R. Impaired phosphoinositide hydrolysis in Alzheimer's disease brain. Neurobiol. Aging 15 (1994) 221-226
88. 3H]idazoxan. Neurosci. Lett. 184 (1995) 133-136
89. Tranquilli Leali F.M., Artico M., Potenza S., and Cavallotti C. Age-related changes of monoaminooxidases in rat cerebellar cortex. Eur. J. Histochem. 47 (2003) 81-86
90. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81 (2001) 741-766
91. Hardy J., and Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297 (2002) 353-356
92. Forman M.S., Trojanowski J.Q., and Lee V.M. Neurodegenerative diseases: a decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 10 (2004) 1055-1063
93. LaFerla F.M., and Oddo S. Alzheimer's disease: Abeta, tau and synaptic dysfunction. Trends Mol. Med. 11 (2005) 170-176
94. Saido T.C., and Iwata N. Metabolism of amyloid beta peptide and pathogenesis of Alzheimer's disease. Towards presymptomatic diagnosis, prevention and therapy. Neurosci. Res. 54 (2006) 235-253
95. Kern A., Roempp B., Prager K., Walter J., and Behl C. Down-regulation of endogenous amyloid precursor protein processing due to cellular aging. J. Biol. Chem. 281 (2006) 2405-2413
96. Saito T., Iwata N., Tsubuki S., Takaki Y., Takano J., Huang S.M., Suemoto T., Higuchi M., and Saido T.C. Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. Nat. Med. 11 (2005) 434-439
97. Howell S., Nalbantoglu J., and Crine P. Neutral endopeptidase can hydrolyze beta-amyloid(1-40) but shows no effect on beta-amyloid precursor protein metabolism. Peptides 16 (1995) 647-652
98. Iwata N., Takaki Y., Fukami S., Tsubuki S., and Saido T.C. Region-specific reduction of A beta-degrading endopeptidase, neprilysin, in mouse hippocampus upon aging. J. Neurosci. Res. 70 (2002) 493-500
99. Yasojima K., Akiyama H., McGeer E.G., and McGeer P.L. Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of beta-amyloid peptide. Neurosci. Lett. 297 (2001) 97-100
100. Yasojima K., McGeer E.G., and McGeer P.L. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 919 (2001) 115-121
101. Wang D.S., Iwata N., Hama E., Saido T.C., and Dickson D.W. Oxidized neprilysin in aging and Alzheimer's disease brains, Biochem. Biophys. Res. Commun. 310 (2003) 236-241
102. Iwata N., Higuchi M., and Saido T.C. Metabolism of amyloid-beta peptide and Alzheimer's disease. Pharmacol. Ther. 108 (2005) 129-148
103. Anagnostaras S.G., Murphy G.G., Hamilton S.E., Mitchell S.L., Rahnama N.P., Nathanson N.M., and Silva A.J. Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat. Neurosci. 6 (2003) 51-58
104. Ferrari-DiLeo G., and Flynn D.D. Diminished muscarinic receptor-stimulated [3H]-PIP2 hydrolysis in Alzheimer's disease. Life Sci. 53 (1993) PL439-PL444
105. Francis P.T., Palmer A.M., Snape M., and Wilcock G.K. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J. Neurol., Neurosurg. Psychiatry 66 (1999) 137-147
106. Minger S.L., Esiri M.M., McDonald B., Keene J., Carter J., Hope T., and Francis P.T. Cholinergic deficits contribute to behavioral disturbance in patients with dementia. Neurology 55 (2000) 1460-1467
107. Lai M.K., Lai O.F., Keene J., Esiri M.M., Francis P.T., Hope T., and Chen C.P. Psychosis of Alzheimer's disease is associated with elevated muscarinic M2 binding in the cortex. Neurology 57 (2001) 805-811
108. Flynn D.D., Weinstein D.A., and Mash D.C. Loss of high-affinity agonist binding to M1 muscarinic receptors in Alzheimer's disease: implications for the failure of cholinergic replacement therapies. Ann. Neurol. 29 (1991) 256-262
109. Masliah E., Cole G.M., Hansen L.A., Mallory M., Albright T., Terry R.D., and Saitoh T. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. J. Neurosci. 11 (1991) 2759-2767
110. Jope R.S. Cholinergic muscarinic receptor signaling by the phosphoinositide signal transduction system in Alzheimer's disease. J. Alzheimers Dis. 1 (1999) 231-247
111. Tsang S.W., Lai M.K., Kirvell S., Francis P.T., Esiri M.M., Hope T., Chen C.P., and Wong P.T. Impaired coupling of muscarinic M(1) receptors to G-proteins in the neocortex is associated with severity of dementia in Alzheimer's disease. Neurobiol. Aging 27 (2006) 1216-1223
112. Ohm T.G., Bohl J., and Lemmer B. Reduced basal and stimulated (isoprenaline, Gpp(NH)p, forskolin) adenylate cyclase activity in Alzheimer's disease correlated with histopathological changes. Brain Res. 540 (1991) 229-236
113. Cowburn R.F., O'Neill C., Ravid R., Alafuzoff I., Winblad B., and Fowler C.J. Adenylyl cyclase activity in postmortem human brain: evidence of altered G protein mediation in Alzheimer's disease. J. Neurochem. 58 (1992) 1409-1419
114. Cowburn R.F., O'Neill C., Ravid R., Winblad B., and Fowler C.J. Preservation of Gi-protein inhibited adenylyl cyclase activity in the brains of patients with Alzheimer's disease. Neurosci. Lett. 141 (1992) 16-20
115. Schnecko A., Witte K., Bohl J., Ohm T., and Lemmer B. Adenylyl cyclase activity in Alzheimer's disease brain: stimulatory and inhibitory signal transduction pathways are differently affected. Brain Res. 644 (1994) 291-296
116. Hashimoto E., Ozawa H., Saito T., Gsell W., Takahata N., Riederer P., and Frolich L. Impairment of G(salpha) function in human brain cortex of Alzheimer's disease: comparison with normal aging. J. Neural Transm. 111 (2004) 311-322
117. Cowburn R.F., Vestling M., Fowler C.J., Ravid R., Winblad B., and O'Neill C. Disrupted beta 1-adrenoceptor-G protein coupling in the temporal cortex of patients with Alzheimer's disease. Neurosci. Lett. 155 (1993) 163-166
118. Huang H.M., and Gibson G.E. Altered beta-adrenergic receptor-stimulated cAMP formation in cultured skin fibroblasts from Alzheimer donors. J. Biol. Chem. 268 (1993) 14616-14621
119. 3H]cAMP binding to cytosolic and particulate protein kinase A in post-mortem brain staged for Alzheimer's disease neurofibrillary changes and amyloid deposits. Brain Res. 818 (1999) 383-396
120. Martinez M., and Mougan I. Fatty acid composition of human brain phospholipids during normal development. J. Neurochem. 71 (1998) 2528-2533
121. Carver J.D., Benford V.J., Han B., and Cantor A.B. The relationship between age and the fatty acid composition of cerebral cortex and erythrocytes in human subjects. Brain Res. Bull. 56 (2001) 79-85
122. Neuringer M., and Connor W.E. n-3 fatty acids in the brain and retina: evidence for their essentiality. Nutr. Rev. 44 (1986) 285-294
123. Neuringer M., Connor W.E., Lin D.S., Barstad L., and Luck S. Biochemical and functional effects of prenatal and postnatal omega 3 fatty acid deficiency on retina and brain in rhesus monkeys. Proc. Natl. Acad. Sci. U. S. A. 83 (1986) 4021-4025
124. Wainwright P.E., Xing H.C., Mutsaers L., McCutcheon D., and Kyle D. Arachidonic acid offsets the effects on mouse brain and behavior of a diet with a low (n-6):(n-3) ratio and very high levels of docosahexaenoic acid. J. Nutr. 127 (1997) 184-193
125. Youdim K.A., Martin A., and Joseph J.A. Essential fatty acids and the brain: possible health implications. Int. J. Dev. Neurosci. 18 (2000) 383-399
126. Walter A., Korth U., Hilgert M., Hartmann J., Weichel O., Fassbender K., Schmitt A., and Klein J. Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol. Aging 25 (2004) 1299-1303
127. Nitsch R.M., Blusztajn J.K., Pittas A.G., Slack B.E., Growdon J.H., and Wurtman R.J. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. U. S. A. 89 (1992) 1671-1675
128. Conquer J.A., Tierney M.C., Zecevic J., Bettger W.J., and Fisher R.H. Fatty acid analysis of blood plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 35 (2000) 1305-1312
129. Ginsberg L., Xuereb J.H., and Gershfeld N.L. Membrane instability, plasmalogen content, and Alzheimer's Disease. J. Neurochem. 70 (1998) 2533-2538
130. Masliah E., Mallory M., Ge N., Alford M., Veinbergs I., and Roses A.D. Neurodegeneration in the central nervous system of apoE-deficient mice. Exp. Neurol. 136 (1995) 107-122
131. Oitzl M.S., Mulder M., Lucassen P.J., Havekes L.M., Grootendorst J., and de Kloet E.R. Severe learning deficits in apolipoprotein E-knockout mice in a water maze task. Brain Res. 752 (1997) 189-196
132. Krzywkowski P., Ghribi O., Gagne J., Chabot C., Kar S., Rochford J., Massicotte G., and Poirier J. Cholinergic systems and long-term potentiation in memory-impaired apolipoprotein E-deficient mice. Neuroscience 92 (1999) 1273-1286
133. Roth G.S., Joseph J.A., and Mason R.P. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci. 18 (1995) 203-206
134. Crook T., Petrie W., Wells C., and Massari D.C. Effects of phosphatidylserine in Alzheimer's disease. Psychopharmacol. Bull. 28 (1992) 61-66
135. Puskas L.G., Kitajka K., Nyakas C., Barcelo-Coblijn G., and Farkas T. Short-term administration of omega 3 fatty acids from fish oil results in increased transthyretin transcription in old rat hippocampus. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 1580-1585
136. Henderson S.T. High carbohydrate diets and Alzheimer's disease. Med. Hypotheses 62 (2004) 689-700
137. Kalmijn S., Launer L.J., Ott A., Witteman J.C., Hofman A., and Breteler M.M. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann. Neurol. 42 (1997) 776-782
138. Grant W.B. Dietary links to Alzheimer's disease: 1999 update. J. Alzheimer's Dis. 1 (1999) 197-201
139. Smith M.A., Petot G.J., and Perry G. Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease. J. Alzheimer's Dis. 1 (1999) 203-206
140. Cooper J.L. Dietary lipids in the aetiology of Alzheimer's disease: implications for therapy. Drugs Aging 20 (2003) 399-418
141. Prasad M.R., Lovell M.A., Yatin M., Dhillon H., and Markesbery W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 23 (1998) 81-88
142. McGeer P.L., and McGeer E.G. Inflammation, autotoxicity and Alzheimer disease. Neurobiol. Aging 22 (2001) 799-809
143. Solfrizzi V., Panza F., Torres F., Mastroianni F., Del Parigi A., Venezia A., Capurso, and High monounsaturated fatty acids intake protects against age-related cognitive decline A. Neurology 52 (1999) 1563-1569
144. Panza F., Solfrizzi V., Colacicco A.M., D'Introno A., Capurso C., Torres F., Del Parigi A., Capurso S., and Capurso A. Mediterranean diet and cognitive decline. Public Health Nutr. 7 (2004) 959-963
145. Acin S., Navarro M.A., Carnicer R., Arbones-Mainar J.M., Guzman M.A., Arnal C., Beltran G., Uceda M., Maeda N., and Osada J. Dietary cholesterol suppresses the ability of olive oil to delay the development of atherosclerotic lesions in apolipoprotein E knockout mice. Atherosclerosis 182 (2005) 17-28
146. Schutzer W.E., and Mader S.L. Age-related changes in vascular adrenergic signaling: clinical and mechanistic implications. Ageing Res. Rev. 2 (2003) 169-190
147. Lakatta E.G. Cardiovascular regulatory mechanisms in advanced age. Physiol. Rev. 73 (1993) 413-467
148. Folkow B., and Svanborg A. Physiology of cardiovascular aging. Physiol. Rev. 73 (1993) 725-764
149. Leineweber K., Wangemann T., Giessler C., Bruck H., Dhein S., Kostelka M., Mohr F.W., Silber R.E., and Brodde O.E. Age-dependent changes of cardiac neuronal noradrenaline reuptake transporter (uptake1) in the human heart. J. Am. Coll. Cardiol. 40 (2002) 1459-1465
150. Seals D.R., and Esler M.D. Human ageing and the sympathoadrenal system. J. Physiol. 528 (2000) 407-417
151. Brodde O.E., and Leineweber K. Autonomic receptor systems in the failing and aging human heart: similarities and differences. Eur. J. Pharmacol. 500 (2004) 167-176
152. Docherty J.R. Cardiovascular responses in ageing: a review. Pharmacol. Rev. 42 (1990) 103-125
153. Ferrara N., Davia K., Abete P., Rengo F., and Harding S.E. Alterations in beta-adrenoceptor mechanisms in the aging heart, relationship with heart failure. Aging 9 (1997) 391-403
154. White M., Roden R., Minobe W., Khan M.F., Larrabee P., Wollmering M., Port J.D., Anderson F., Campbell D., Feldman A.M., et al. Age-related changes in beta-adrenergic neuroeffector systems in the human heart. Circulation 90 (1994) 1225-1238
155. Brodde O.E., Zerkowski H.R., Schranz D., Broede-Sitz A., Michel-Reher M., Schafer-Beisenbusch E., Piotrowski J.A., and Oelert H. Age-dependent changes in the beta-adrenoceptor-G-protein(s)-adenylyl cyclase system in human right atrium. J. Cardiovasc. Pharmacol. 26 (1995) 20-26
156. Brodde O.E., Konschak U., Becker K., Ruter F., Poller U., Jakubetz J., Radke J., and Zerkowski H.R. Cardiac muscarinic receptors decrease with age. In vitro and in vivo studies. J. Clin. Invest. 101 (1998) 471-478
157. Giessler C., Wangemann T., Zerkowski H.R., and Brodde O.E. Age-dependent decrease in the negative inotropic effect of carbachol on isolated human right atrium. Eur. J. Pharmacol. 357 (1998) 199-202
158. Leineweber K., Klapproth S., Beilfuss A., Silber R.E., Heusch G., Philipp T., and Brodde O.E. Unchanged G-protein-coupled receptor kinase activity in the aging human heart. J. Am. Coll. Cardiol. 42 (2003) 1487-1492
159. Roka F., Freissmuth M., and Nanoff C. G protein-dependent signalling and ageing. Exp. Gerontol. 35 (2000) 133-143
160. Werstiuk E.S., and Lee R.M. Vascular beta-adrenoceptor function in hypertension and in ageing. Can. J. Physiol. Pharmacol. 78 (2000) 433-452
161. Bonnevier J., Fassler R., Somlyo A.P., Somlyo A.V., and Arner A. Modulation of Ca2+sensitivity by cyclic nucleotides in smooth muscle from protein kinase G-deficient mice. J. Biol. Chem. 279 (2004) 5146-5151
162. Gaballa M.A., Eckhart A.D., Koch W.J., and Goldman S. Vascular beta-adrenergic receptor adenylyl cyclase system in maturation and aging. J. Mol. Cell Cardiol. 32 (2000) 1745-1755
163. Schutzer W.E., Reed J.F., Bliziotes M., and Mader S.L. Upregulation of G protein-linked receptor kinases with advancing age in rat aorta. Am. J. Physiol., Regul. Integr. Comp. Physiol. 280 (2001) R897-R903
164. Gurdal H., Friedman E., and Johnson M.D. Beta-adrenoceptor-G alpha S coupling decreases with age in rat aorta. Mol. Pharmacol. 47 (1995) 772-778
165. Schutzer W.E., Watts V.J., Chapman J., Cumbay M.G., Neve K.A., Neve R.L., and Mader S.L. Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity. Clin. Exp. Pharmacol. Physiol. 27 (2000) 9-13
166. Benetos A., Huguet F., Albaladejo P., Brisac A.M., Pappo M., Safar M.E., and Levy B.I. Role of adrenergic tone in mechanical and functional properties of carotid artery during aging. Am. J. Physiol. 265 (1993) H1132-H1138
167. Johnson M.D., Zhou Y., Friedman E., and Roberts J. Expression of G protein alpha subunits in the aging cardiovascular system. J. Gerontol., A, Biol. Sci. Med. Sci. 50A (1995) B14-B19
168. Mader S.L., Downing C.L., Amos-Landgraf J., and Swebjka P. Age-related changes in G proteins in rat aorta. J. Gerontol., A, Biol. Sci. Med. Sci. 51 (1996) B111-B116
169. Chapman J., Cohen-Armon M., Shoenfeld Y., and Korczyn A.D. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 8 (1999) 127-133
170. Zheng B., Ma Y.C., Ostrom R.S., Lavoie C., Gill G.N., Insel P.A., Huang X.Y., and Farquhar M.G. RGS-PX1, a GAP for GalphaS and sorting nexin in vesicular trafficking. Science 294 (2001) 1939-1942
171. Ollerenshaw J.D., Heagerty A.M., Bing R.F., and Swales J.D. Abnormalities of erythrocyte membrane fatty acid composition in human essential hypertension. J. Hum. Hypertens. 1 (1987) 9-12
172. + countertransport in essential hypertension: correlation with membrane lipids levels. J. Hypertens. 14 (1996) 969-973
173. Russo C., Olivieri O., Girelli D., Guarini P., Pasqualini R., Azzini M., and Corrocher R. Increased membrane ratios of metabolite to precursor fatty acid in essential hypertension. Hypertension 29 (1997) 1058-1063
174. Mata P., Garrido J.A., Ordovas J.M., Blazquez E., Alvarez-Sala L.A., Rubio M.J., Alonso R., and de Oya M. Effect of dietary monounsaturated fatty acids on plasma lipoproteins and apolipoproteins in women. Am. J. Clin. Nutr. 56 (1992) 77-83
175. Heyden S. Polyunsaturated and monounsaturated fatty acids in the diet to prevent coronary heart disease via cholesterol reduction. Ann. Nutr. Metab. 38 (1994) 117-122
176. Ruiz-Gutierrez V., Muriana F.J., Guerrero A., Cert A.M., and Villar J. Plasma lipids, erythrocyte membrane lipids and blood pressure of hypertensive women after ingestion of dietary oleic acid from two different sources. J. Hypertens. 14 (1996) 1483-1490
177. Muriana F.J., Montilla C., Villar J., and Ruiz-Gutierrez V. Transbilayer movement of erythrocyte membrane cholesterol in human essential hypertension. J. Hypertens. 13 (1995) 619-623
178. Muriana F.J., Alonso A., Villar J., and Ruiz-Gutierrez V. Validity of studies on distribution and transbilayer movement of erythrocyte membrane cholesterol. J. Hypertens. 14 (1996) 1379-1380
179. Muriana F.J., Villar J., and Ruiz-Gutierrez V. Intake of olive oil can modulate the transbilayer movement of human erythrocyte membrane cholesterol. Cell Mol. Life Sci. 53 (1997) 496-500
180. Ruiz-Gutierrez V., Perona J.S., Pacheco Y.M., Muriana F.J., and Villar J. Incorporation of dietary triacylglycerols from olive oil and high-oleic sunflower oil into VLDL triacylglycerols of hypertensive patients. Eur. J. Clin. Nutr. 53 (1999) 687-693
181. Perona J.S., Canizares J., Montero E., Sanchez-Dominguez J.M., and Ruiz-Gutierrez V. Plasma lipid modifications in elderly people after administration of two virgin olive oils of the same variety (Olea europaea var. hojiblanca) with different triacylglycerol composition. Br. J. Nutr. 89 (2003) 819-826
182. North P., and Fleischer S. Alteration of synaptic membrane cholesterol/phospholipid ratio using a lipid transfer protein. Effect on gamma-aminobutyric acid uptake. J. Biol. Chem. 258 (1983) 1242-1253
183. Tsuda K., Kimura K., Nishio I., and Masuyama Y. Nitric oxide improves membrane fluidity of erythrocytes in essential hypertension: An electron paramagnetic resonance investigation. Biochem. Biophys. Res. Commun. 275 (2000) 946-954
184. Cimino M., Vantini G., Algeri S., Curatola G., Pezzoli C., and Stramentinoli G. Age-related modification of dopaminergic and beta-Adrenergic receptor system: restoration to normal activity by modifying membrane fluidity with S-adenosylmethionine. Life Sci. 34 (1984) 2029-2039
185. Prades J., Funari S.S., Escriba P.V., and Barcelo F. Effects of unsaturated fatty acids and triacylglycerols on phosphatidylethanolamine membrane structure. J. Lipid Res. 44 (2003) 1720-1727
186. Alemany R., Vogler O., Teres S., Egea C., Baamonde C., Barcelo F., Delgado C., Jakobs K.H., and Escriba P.V. Antihypertensive action of 2-hydroxyoleic acid in SHR mediated by enhancement of the protein kinase A pathway and downregulation of Rho-kinase. J. Lipid Res. 47 (2006) 1762-1770
187. Tsvetkova N.M., Horvath I., Torok Z., Wolkers W.F., Balogi Z., Shigapova N., Crowe L.M., Tablin F., Vierling E., Crowe J.H., and Vigh L. Small heat-shock proteins regulate membrane lipid polymorphism. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 13504-13509